Credit Suisse’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-330,524
| Closed | -$17.3M | – | 4570 |
|
|
2020
Q3 | $17.3M | Buy |
330,524
+166,001
| +101% | +$6.87M | 0.01% | 1107 |
|
|
2020
Q2 | $5.47M | Buy |
164,523
+82,352
| +100% | +$2.62M | ﹤0.01% | 1654 |
|
|
2020
Q1 | $2.23M | Buy |
82,171
+11,427
| +16% | +$318K | ﹤0.01% | 2061 |
|
|
2019
Q4 | $1.4M | Buy |
70,744
+3,984
| +6% | +$63.7K | ﹤0.01% | 2896 |
|
|
2019
Q3 | $866K | Buy |
66,760
+1,643
| +3% | +$19.8K | ﹤0.01% | 3107 |
|
|
2019
Q2 | $811K | Buy |
65,117
+805
| +1% | +$10.7K | ﹤0.01% | 3091 |
|
|
2019
Q1 | $934K | Buy |
64,312
+14,738
| +30% | +$188K | ﹤0.01% | 2945 |
|
|
2018
Q4 | $548K | Buy |
49,574
+6,159
| +14% | +$85.7K | ﹤0.01% | 3195 |
|
|
2018
Q3 | $1.14M | Sell |
43,415
-24,523
| -36% | -$663K | ﹤0.01% | 2765 |
|
|
2018
Q2 | $1.39M | Sell |
67,938
-5,769
| -8% | -$124K | ﹤0.01% | 2768 |
|
|
2018
Q1 | $1.34M | Sell |
73,707
-21,714
| -23% | -$362K | ﹤0.01% | 2750 |
|
|
2017
Q4 | $1.33M | Sell |
95,421
-15,175
| -14% | -$205K | ﹤0.01% | 2775 |
|
|
2017
Q3 | $2.05M | Buy |
110,596
+26,611
| +32% | +$445K | ﹤0.01% | 2527 |
|
|
2017
Q2 | $1.42M | Sell |
83,985
-37,113
| -31% | -$565K | ﹤0.01% | 2461 |
|
|
2017
Q1 | $1.62M | Buy |
121,098
+43,685
| +56% | +$684K | ﹤0.01% | 2508 |
|
|
2016
Q4 | $1.17M | Buy |
77,413
+10,081
| +15% | +$133K | ﹤0.01% | 2904 |
|
|
2016
Q3 | $788K | Sell |
67,332
-6,859
| -9% | -$80.6K | ﹤0.01% | 3140 |
|
|
2016
Q2 | $801K | Buy |
74,191
+3,495
| +5% | +$36.1K | ﹤0.01% | 3105 |
|
|
2016
Q1 | $653K | Buy |
70,696
+3,514
| +5% | +$37.8K | ﹤0.01% | 3047 |
|
|
2015
Q4 | $997K | Buy |
67,182
+26,529
| +65% | +$444K | ﹤0.01% | 2814 |
|
|
2015
Q3 | $666K | Sell |
40,653
-99,587
| -71% | -$2.04M | ﹤0.01% | 3181 |
|
|
2015
Q2 | $3.2M | Buy |
140,240
+101,460
| +262% | +$2.02M | ﹤0.01% | 2152 |
|
|
2015
Q1 | $589K | Sell |
38,780
-17,616
| -31% | -$229K | ﹤0.01% | 3430 |
|
|
2014
Q4 | $679K | Buy |
56,396
+30,227
| +116% | +$345K | ﹤0.01% | 3475 |
|
|
2014
Q3 | $296K | Sell |
26,169
-536,558
| -95% | -$6.12M | ﹤0.01% | 3937 |
|
|
2014
Q2 | $6.8M | Buy |
562,727
+90,189
| +19% | +$1.07M | 0.01% | 1682 |
|
|
2014
Q1 | $5.51M | Buy |
472,538
+364,691
| +338% | +$6.18M | 0.01% | 1681 |
|
|
2013
Q4 | $1.91M | Sell |
107,847
-109,615
| -50% | -$1.84M | ﹤0.01% | 2687 |
|
|
2013
Q3 | $3.13M | Buy |
217,462
+127,446
| +142% | +$1.95M | ﹤0.01% | 2017 |
|
|
2013
Q2 | $1.36M | Buy |
+90,016
| New | +$1.19M | ﹤0.01% | 2562 |
|
Credit Suisse's MNTA Position: Q4 2020 in Review
Credit Suisse sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 330,524 shares — an estimated $17.3M sold.
Credit Suisse first reported a position in MNTA in Q2 2013 and held it in 30 quarters. The position peaked at $17.3M in Q3 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- Credit Suisse reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- Credit Suisse sold 330,524 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $17.3M.
- Credit Suisse first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 30 quarters.
- Credit Suisse's Momenta Pharmaceuticals, Inc. position peaked at $17.3M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on Credit Suisse's 13F filing for Q4 2020, filed 12 Feb 2021.